Caligan Partners as of Sept. 30, 2025
Portfolio Holdings for Caligan Partners
Caligan Partners holds 17 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Liquidia Corporation Com New (LQDA) | 24.2 | $185M | 8.1M | 22.74 | |
| Abivax Sa Sponsored Ads (ABVX) | 16.1 | $123M | 1.5M | 84.90 | |
| Mineralys Therapeutics (MLYS) | 13.8 | $105M | 2.8M | 37.92 | |
| Agios Pharmaceuticals (AGIO) | 11.1 | $85M | 2.1M | 40.14 | |
| Exelixis (EXEL) | 8.3 | $63M | 1.5M | 41.30 | |
| Revolution Medicines (RVMD) | 6.5 | $50M | 1.1M | 46.70 | |
| Adma Biologics (ADMA) | 5.1 | $39M | 2.6M | 14.66 | |
| Evolus (EOLS) | 3.3 | $25M | 4.1M | 6.14 | |
| Merus N V (MRUS) | 2.7 | $20M | 217k | 94.15 | |
| Xenon Pharmaceuticals (XENE) | 2.3 | $18M | 445k | 40.15 | |
| Anika Therapeutics (ANIK) | 1.8 | $14M | 1.4M | 9.40 | |
| Avalo Therapeutics Com New (AVTX) | 1.4 | $11M | 833k | 12.71 | |
| Tyra Biosciences (TYRA) | 1.3 | $9.7M | 697k | 13.99 | |
| Inhibrx Biosciences (INBX) | 1.0 | $8.0M | 236k | 33.68 | |
| Verrica Pharmaceuticals Com Shs (VRCA) | 0.5 | $4.0M | 924k | 4.31 | |
| Sellas Life Sciences Group I Com New Call Option (SLS) | 0.5 | $3.7M | 2.3M | 1.61 | |
| Aura Biosciences (AURA) | 0.2 | $1.4M | 227k | 6.18 |
